Home › Funds › CAPSTONE INVESTMENT ADVISORS, LLC › ALNY
CAPSTONE INVESTMENT ADVISORS, LLC position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
CAPSTONE INVESTMENT ADVISORS, LLC reported holding 58,700,000 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$53.9M, representing 0.53% of its reported portfolio and ranking #31 among its reported holdings. CAPSTONE INVESTMENT ADVISORS, LLC has disclosed ALNY holdings in 12 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How CAPSTONE INVESTMENT ADVISORS, LLC's ALNY position evolved
CAPSTONE INVESTMENT ADVISORS, LLC first disclosed a stake in ALNY in Q3 2023 at 10,000,000 shares (US$9.3M). The position peaked in Q3 2026 at 58,700,000 shares, worth US$53.9M. Across 12 filings, CAPSTONE INVESTMENT ADVISORS, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 58,700,000 shares valued at US$53.9M — an increase of 58,698,101 shares quarter over quarter.. Notable position changes include a 453621% increase in Q4 2024 (shares rose 15% over the following quarter), a 331% increase in Q4 2025 (shares fell 17% over the following quarter), a 3091001% increase in Q3 2026 (shares fell 33% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 10.00M | $9.28M | New |
| Q4 2023 | 17.50M | $17.28M | Add |
| Q1 2024 | 12.50M | $11.81M | Reduce |
| Q2 2024 | 7.50M | $8.10M | Reduce |
| Q3 2024 | 1.65K | $454.62K | Reduce |
| Q4 2024 | 7.50M | $7.99M | Add |
| Q1 2025 | 7.50M | $8.65M | Hold |
| Q3 2025 | 1.23K | $561.34K | New |
| Q4 2025 | 5.30K | $2.11M | Add |
| Q1 2026 | 753 | $249.15K | Reduce |
| Q2 2026 | 1.90K | $571.66K | Add |
| Q3 2026 | 58.70M | $53.90M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$597.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 5.49M sh · $1.36B · Q3 2026
- Orbis Allan Gray Ltd 2.42M sh · $597.40M · Q3 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
More on CAPSTONE INVESTMENT ADVISORS, LLC
FAQ
How long has CAPSTONE INVESTMENT ADVISORS, LLC held ALNY?
CAPSTONE INVESTMENT ADVISORS, LLC has disclosed ALNY holdings in 12 of the last 13 reported quarters, going back to Q3 2023.
What is CAPSTONE INVESTMENT ADVISORS, LLC's current position in ALNY?
As of Q3 2026, CAPSTONE INVESTMENT ADVISORS, LLC holds 58.70M shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $53.90M, representing 0.53% of its reported portfolio and ranking #31.
Has CAPSTONE INVESTMENT ADVISORS, LLC been buying or selling ALNY?
In the latest 13F filing (Q3 2026), CAPSTONE INVESTMENT ADVISORS, LLC increased its position in ALNY. The position peaked in Q3 2026 at 58.70M shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.